Search - tctmd.com

Displaying 1 - 20 of 59

Sort: Relevancy | Date

Presentation THT 2026

Healthcare Systems Harnessing Their Own Data for Evidence, Generation, Dissemination, and Influencing Clinical Practice — Example 2

Presenter: Nir Uriel

March 04, 2026

Presentation THT 2026

How Will Guideline Committees View Results From RWE Trials?

Presenter: Paul Heidenrich

March 04, 2026

Presentation THT 2026

AHA and C3TN Shock Networks

Presenter: Shashank Shekhar Sinha

March 04, 2026

Presentation THT 2026

Cardiogenic Shock Working Group: Triumphs and Tribulations

Presenter: Rachna Kataria

March 04, 2026

Presentation THT 2026

Hemodynamic Frontiers in Heart Failure (HF2) Registry: Goals and Achievements

Presenter: Tom Heywood

March 04, 2026

Presentation THT 2026

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Presenter: Tor Biering-Sørensen

March 04, 2026

Presentation THT 2026

Statistical Approaches for Developing Credible Evidence of Safety and Effectiveness for HF Devices From Real World Data: An Overview for the Clinician

Presenter: Issa Dahabreh

March 04, 2026

Presentation THT 2026

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Presenter: Robert W. Yeh

March 04, 2026

Presentation THT 2026

Time for a Separate Guideline Path for HF Devices?

Presenter: Javed Butler

March 04, 2026

Presentation THT 2026

Clinical Feasibility Study of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in Patients with Cardiogenic Shock (ELEVATE™ CS FIH)

Presenter: David Israeli

March 04, 2026

Presentation THT 2026

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

Presenter: James Januzzi

March 04, 2026

Presentation THT 2026

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Presenter: Gregg W. Stone

March 04, 2026

Presentation THT 2026

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

Presenter: John A. Spertus

March 04, 2026

Presentation THT 2026

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

Presenter: JoAnn Lindenfeld

March 04, 2026

Presentation THT 2026

Beyond Survival: Defining Success After Total Artificial Heart Implantation

Presenter: Andre Simon

March 04, 2026

Presentation THT 2026

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Presenter: Sheldon E. Litwin

March 04, 2026

Presentation THT 2026

Design and Conduct of the INNOVATE Trial: Randomizing Durable LVAD Therapy in a High-Acuity Era

Presenter: Francis D. Pagani

March 04, 2026

Presentation THT 2026

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Presenter: Beth A. Davison

March 04, 2026

Presentation THT 2026

Physiology and Hemodynamics of Left Atrial to Coronary Sinus Shunting: Potential Implications for Clinical Effectiveness

Presenter: Ryan J. Tedford

March 04, 2026

Presentation THT 2026

Impella-Bridge Strategy Tended To Be Associated With Lower Mortality Following Durable Left Ventricular Assist Device Implantation In Japan

Presenter: Makiko Nakamura

March 04, 2026

Advertisement

Healthcare Systems Harnessing Their Own Data for Evidence, Generation, Dissemination, and Influencing Clinical Practice — Example 2

How Will Guideline Committees View Results From RWE Trials?

AHA and C3TN Shock Networks

Cardiogenic Shock Working Group: Triumphs and Tribulations

Hemodynamic Frontiers in Heart Failure (HF2) Registry: Goals and Achievements

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Statistical Approaches for Developing Credible Evidence of Safety and Effectiveness for HF Devices From Real World Data: An Overview for the Clinician

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Time for a Separate Guideline Path for HF Devices?

Clinical Feasibility Study of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in Patients with Cardiogenic Shock (ELEVATE™ CS FIH)

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

Beyond Survival: Defining Success After Total Artificial Heart Implantation

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Design and Conduct of the INNOVATE Trial: Randomizing Durable LVAD Therapy in a High-Acuity Era

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Physiology and Hemodynamics of Left Atrial to Coronary Sinus Shunting: Potential Implications for Clinical Effectiveness

Impella-Bridge Strategy Tended To Be Associated With Lower Mortality Following Durable Left Ventricular Assist Device Implantation In Japan

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content